Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo
- PMID: 9824051
Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo
Abstract
Vaccination of mouse myeloma V(K)C(K)-gamma (I) cells secreting interferon (IFN)-gamma and expressing enhanced major histocompatibility complex (MHC) class I antigen (Ag) resulted in protective immunity that was mainly mediated by CD8+ T cells. V(K)C(K)-gamma (I/II) cells expressing both enhanced MHC class I and class II Ags were isolated from V(K)C(K)-gamma (I) cells. These V(K)C(K)-gamma (I/II) cells were used to study the relationship between IFN-gamma secretion of tumor cells, its tumorigenicity, and its induced immunity, as well as to evaluate the cellular immunocomponents mediating this immunity. Our animal studies showed that IFN-gamma secretion by V(K)C(K)-gamma (I/II) cells curtailed its tumorigenicity in syngeneic BALB/c mice and further induced protective immunity against a subsequent graft of parental V(K)C(K) tumor. This immunity is mediated by both CD4+ and CD8+ T cells. The activation of CD4+ T cells is associated with enhanced expression of MHC class II Ag of V(K)C(K)-gamma (I/II) cells. These CD4+ T cells are tumor specific and cytolytic in an MHC-restricted fashion in vitro, and are tumoricidal in a T-cell adoptive transfer experiment in vivo. Our data thus demonstrate that vaccination of genetically modified tumor cells secreting IFN-gamma may provide beneficial antitumor effects by inducing both cytolytic CD4+ and CD8+ cytotoxic T lymphocytes, provided that these tumor cells express both enhanced MHC class I and class II Ags.
Similar articles
-
Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.J Immunol. 1995 May 1;154(9):4613-22. J Immunol. 1995. PMID: 7722313
-
Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.Cancer Res. 2002 Apr 1;62(7):2043-51. Cancer Res. 2002. PMID: 11929823
-
Lymphocyte-mediated activation of cultured endothelial cells (EC). CD4+ T cells inhibit EC class II MHC expression despite secreting IFN-gamma and increasing EC class I MHC and intercellular adhesion molecule-1 expression.J Immunol. 1990 Aug 15;145(4):1088-98. J Immunol. 1990. PMID: 1974272
-
MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.J Immunother. 2001 May-Jun;24(3):195-204. J Immunother. 2001. PMID: 11394496 Review.
-
Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood γδ T-lymphocytes.J Immunotoxicol. 2012 Jul-Sep;9(3):259-66. doi: 10.3109/1547691X.2012.685528. Epub 2012 May 27. J Immunotoxicol. 2012. PMID: 22632132 Review.
Cited by
-
Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity.Cancer Immunol Immunother. 2011 Oct;60(10):1473-84. doi: 10.1007/s00262-011-1054-y. Epub 2011 Jun 10. Cancer Immunol Immunother. 2011. PMID: 21660450 Free PMC article.
-
A distinct role of CD4+ Th17- and Th17-stimulated CD8+ CTL in the pathogenesis of type 1 diabetes and experimental autoimmune encephalomyelitis.J Clin Immunol. 2011 Oct;31(5):811-26. doi: 10.1007/s10875-011-9549-z. Epub 2011 Jun 15. J Clin Immunol. 2011. PMID: 21674137 Free PMC article.
-
Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.Aging (Albany NY). 2021 Apr 4;13(8):11381-11410. doi: 10.18632/aging.202831. Epub 2021 Apr 4. Aging (Albany NY). 2021. PMID: 33839701 Free PMC article.
-
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.J Immunol Res. 2014;2014:326545. doi: 10.1155/2014/326545. Epub 2014 Jun 9. J Immunol Res. 2014. PMID: 25009822 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials